Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 3 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Recs

0
Player Avatar 2trpop (30.91) Submitted: 2/7/2012 10:05:17 AM : Outperform Start Price: $120.46 BIIB Score: +10.50

This one seems like cheating.

Featured Broker Partners


Advertisement